FIELD: biotechnology; medicine.
SUBSTANCE: group of inventions relates namely to a monoclonal antibody or its antigen-binding fragment, which specifically binds to GD2 (GD2 ganglioside). The invention also relates to nucleic acids encoding the said antibody, expression vectors, host cells and methods for their production, methods for producing antibodies of the invention, pharmaceutical compositions containing an antibody of the invention, pharmaceutical compositions containing an antibody of the invention and other therapeutically active compounds, methods treatment of GD2 mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof for the treatment of GD2 mediated diseases or disorders, and uses of the antibodies of the invention and other therapeutically active compounds for the treatment of GD2 mediated diseases or disorders.
EFFECT: invention makes it possible to obtain new antibodies with high affinity for HLA-G.
73 cl, 6 dwg, 11 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-AFFINITY ANTI-GD2 ANTIBODIES | 2014 |
|
RU2680267C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| GD2 BINDING MOLECULE | 2020 |
|
RU2824670C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY | 2014 |
|
RU2679715C1 |
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
